TS
ADPT icon

Thomas Steyer’s Adaptive Biotechnologies ADPT Stock Holding History

Thomas Steyer’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,000
Closed -$153K – 90
2026
Q1 		$153K Hold
11,000
– – ﹤0.01% 155
2025
Q4 		$179K Buy
+11,000
New +$180K ﹤0.01% 140
2019
Q3 		– Sell
-25,000
Closed -$1.21M – 100
2019
Q2 		$1.21M Buy
+25,000
New +$1.11M 0.01% 102

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Thomas Steyer's ADPT Position: Q2 2026 in Review

Thomas Steyer sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 11,000 shares — an estimated $153K sold.

Thomas Steyer first reported a position in ADPT in Q2 2019 and held it in 3 quarters. The position peaked at $1.21M in Q2 2019. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Thomas Steyer reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 11,000 Adaptive Biotechnologies shares in Q2 2026, an estimated $153K.
  • Thomas Steyer first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 3 quarters.
  • Thomas Steyer's Adaptive Biotechnologies position peaked at $1.21M in Q2 2019.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.